YOLFTbeta
20

EuBiologics Co. Ltd.

206650 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

8,000.00KRW-10.00 (-0.12%)

Price History

Full chart

Market Stats

Previous Close8,010.00
Open8,290.00
Day Range8,000.00 – 8,660.00
52-Week Range6,950.00 – 17,700.00
Volume250.94K
Market Cap307.15B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.19
50-Day Avg8,516.00
200-Day Avg11,046.85

About

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein vaccine under the rCRM197 name; and biopharmaceutical contract research and manufacturing, and contract testing services. Further, the company engages in the development of and support for the manufacturing technologies of biomedicines. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yeong-Ok Baik
  • Employees0
  • HeadquartersSD Biosensor Building, Seoul, South Korea, Korea
  • Websitehttps://eubiologics.com

Leadership

  • Mr. Yeong-Ok BaikCEO, Head of Production, Quality, R&D and Director · b. 1962
  • Tae-Young HeoCEO, Head of Management Administration & Director · b. 1969
  • Mr. Kyeong-Ho MinVP & Head of Production · b. 1968
  • Mr. Chan-kyu LeeVP & Head of Research and Development

Financials

Income Statement

Currency: KRW2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Revenue39.38B55.47B69.37B96.04B149.20B
Growth (%)-+40.83%+25.06%+38.45%+55.35%
Cost of Revenue24.12B31.85B35.35B40.08B63.00B
Gross Profit15.26B23.61B34.02B55.95B86.20B
Gross Margin38.75%42.57%49.04%58.26%57.77%
Operating Expense22.49B28.23B48.23B30.20B25.53B
Operating Income-7.23B-4.61B-14.21B25.75B60.66B
Operating Margin-18.36%-8.32%-20.48%26.82%40.66%
EBITDA-5.05B-4.39B29.67B64.80B
EBITDA Margin-9.11%-6.33%30.90%43.43%
Net Income-27.57B-1.10B-13.88B19.12B41.26B
Net Income Margin-70.01%-1.98%-20.01%19.91%27.66%
R&D16.18B15.78B17.88B13.01B13.21B
R&D as % of Total Revenue41.08%28.44%25.78%13.54%8.85%
Interest Expense838.11M508.29M1.05B1.14B994.40M
Interest Expense % of Total Revenue2.13%0.92%1.52%1.19%0.67%

Balance Sheet

Currency: KRW2021-09-302022-09-302023-09-302024-09-302025-09-30
Total Assets150.44B162.07B151.81B202.08B240.23B
Total Liabilities30.44B42.63B40.43B70.05B64.87B
Total Equity120.00B124.51B111.37B132.03B175.36B
Cash5.73B11.04B5.13B6.41B23.67B
Net Debt5.97B1.46B2.36B--

Cash Flow

Currency: KRW2020-09-302021-09-302022-09-302023-09-302024-09-302025-09-30
Operating Cash Flow--7.60B6.44B26.45B43.21B49.10B
Investing Cash Flow---2.13B-28.11B-27.00B-
Financing Cash Flow--634.58M566.03M-3.81B-
Capital Expenditure09.16B25.24B43.66B11.82B16.96B
Free Cash Flow--16.76B-18.80B-17.21B31.39B32.14B
FCF to OCF-220.48%-291.85%-65.04%72.65%65.46%

Earnings

Report DateMay 12, 2017Aug 14, 2017Nov 16, 2017Feb 12, 2018May 3, 2018Aug 14, 2018Nov 13, 2018Jan 30, 2019May 7, 2019Aug 14, 2019Nov 6, 2019Feb 6, 2020May 14, 2020Aug 14, 2020Nov 13, 2020Feb 9, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual-35.71-56.48-47.20-41.3981.1278.00-89.6132.76-37.58-169.58319.89-136.09249.55-409.50-2131.25187.63-85.73-757.0057.26-97.673.2647.336.85-87.57-2.9155.84-85.10-348.63-99.17-43.59439.45225.29429.61211.04474.3611.2999.79204.06
Surprise--------------------------------------
TimingPre-marketPre-marketAfter-hoursPre-market--Pre-marketAfter-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketPre-market----------------------

Key Statistics & Ratios

Market Cap307.15B
Enterprise Value234.20B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.20
Price / Book1.64
Revenue (TTM)96.04B
Gross Profit (TTM)96.04B
EBITDA16.87B
Profit Margin25.89%
Operating Margin35.19%
Return on Equity-13.70%
Return on Assets3.07%
Shares Outstanding36.22M
Shares Float29.14M
Beta0.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%